血小板膜蛋白结构稳定剂对高原肺心病肺动脉高压治疗作用的研究

EFFECTS OF TICLID ON PULMONARY HEART DISEASE AND HYPERTENSION AT HIGH ALTITUDE

目的 :探讨抵克利得 (Ticlid,噻氯匹定 )对高原肺心病 (HCP)肺动脉高压(PAHP)的治疗作用及其机理 ;方法 :将HCP患者随机分为抵克利得治疗组 (抵克利得2 5 0mg ,2 /日 ,n =3 0 )和对照治疗组 (常规治疗 ,n =3 0 ) ,全程治疗 4周 ,治疗前后均运用多克隆抗体、流式细胞仪等技术对 60例HCP患者进行血小板膜结合纤维蛋白原 (FG) ,血小板膜糖蛋白 (GP)Ⅲa免疫荧光测定和心功能检查 ;结果 :①抵克利得治疗后血小板膜结合GF和GPⅢa较治疗前有明显降低 ;②抵克利得组肺动脉压和肺动脉阻力 ,治疗后较治疗前有明显降低 ,且明显优于对照治疗组 ;③抵克利得组呼吸功能治疗后较治疗前有明显改善 ;结论 :抵克利得组有明显血小板膜保护作用 。

To study the effects of Ticlid on high altitude cor pulmonale(HCP) and pulmonary hypertension.Method:60 subjects with HCP were divided into therapeutic group (n=30),Ticlid 250mg/day)and control (n=30,general cure).Level of FG,GP were examined before and after treatment with Ticlid.Result:Level of FG,GPⅢa was significantly higher after treatment than that before.The pulmonary pressure was decreased after treatment compared with before treatment,and it was lower in therapeutic group than in control.There is a better pulmonary function after cure than before.Conclusions:Ticlid is a drug that can provent the platelet memberant and descrease the pulmonary hypertension at high altitde.